PMID- 23593411
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - In vitro and in vivo effect of 5-FC combined gene therapy with TNF-alpha and CD 
      suicide gene on human laryngeal carcinoma cell line Hep-2.
PG  - e61136
LID - 10.1371/journal.pone.0061136 [doi]
LID - e61136
AB  - This study was aimed to investigate the effect of combined cancer gene therapy 
      with exogenous tumor necrosis factor-alpha (TNF-alpha) and cytosine deaminase (CD) 
      suicide gene on laryngeal carcinoma cell line Hep-2 in vitro and in vivo. 
      Transfection of the recombinant eukaryotic vectors of pcDNA3.1 (+) containing 
      TNF-alpha and/or CD into Hep-2 cells resulted in expression of TNF-alpha and/or CD gene 
      in vitro. The significant increase in apoptotic Hep-2 cells and decrease of Hep-2 
      cell proliferation were observed using 5-FC treatment combined with TNF-a 
      expression by CD/5-FC suicide system. Moreover, bystander effect was also 
      observed in the TNF-alpha and CD gene co-expression group. Laryngeal squamous cell 
      carcinoma (LSCC) mice model was established by using BALB/c mice which different 
      transfected Hep-2 cells with pcDNA3.1 (+) containing TNF-alpha and/or CD were applied 
      subcutaneously. So these mice are divided into four groups, namely, (1)Hep-2/TIC 
      group; (2)Hep-2/CD group; (3)Hep-2/TNF-alpha group; (4)Hep-2/0 group. At day 29 after 
      cell inoculation, volume of grafted tumor had significant difference between each 
      two of them (P<0.05). These results showed that the products of combined CD and 
      TNF-alpha genes inhibited the growth of transplanted LSCC in mice model. So by our 
      observed parameters and many others results, we hypothesized that 5-FC combined 
      gene therapy with TNF-alphaand CD suicide gene should be an effective treatment on 
      Laryngeal carcinoma.
FAU - Chai, Li-Ping
AU  - Chai LP
AD  - Department of Otolaryngology, First Affiliated Hospital and Otolaryngology 
      Institute, Sun Yat-Sen University, Guangzhou, Guangdong, PR China. 
      clp58612@163.com
FAU - Wang, Zhang-Feng
AU  - Wang ZF
FAU - Liang, Wei-Ying
AU  - Liang WY
FAU - Chen, Lei
AU  - Chen L
FAU - Chen, Dan
AU  - Chen D
FAU - Wang, An-Xun
AU  - Wang AX
FAU - Zhang, Zhao-Qiang
AU  - Zhang ZQ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130411
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (DNA Primers)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - D83282DT06 (Flucytosine)
RN  - EC 3.5.4.1 (Cytosine Deaminase)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Carcinoma, Squamous Cell/drug therapy/genetics/*therapy
MH  - Cell Line, Tumor
MH  - Cloning, Molecular
MH  - Cytosine Deaminase/*genetics/metabolism
MH  - DNA Primers/genetics
MH  - Escherichia coli
MH  - Flucytosine/*therapeutic use
MH  - Genes, Transgenic, Suicide/*genetics
MH  - Genetic Therapy/*methods
MH  - Genetic Vectors
MH  - Humans
MH  - Laryngeal Neoplasms/drug therapy/genetics/*therapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Transfection
MH  - Tumor Necrosis Factor-alpha/*genetics/metabolism
PMC - PMC3623900
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2013/04/18 06:00
MHDA- 2013/10/18 06:00
PMCR- 2013/04/11
CRDT- 2013/04/18 06:00
PHST- 2012/09/10 00:00 [received]
PHST- 2013/03/05 00:00 [accepted]
PHST- 2013/04/18 06:00 [entrez]
PHST- 2013/04/18 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
PHST- 2013/04/11 00:00 [pmc-release]
AID - PONE-D-12-27688 [pii]
AID - 10.1371/journal.pone.0061136 [doi]
PST - epublish
SO  - PLoS One. 2013 Apr 11;8(4):e61136. doi: 10.1371/journal.pone.0061136. Print 2013.